Biotechnology

Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

September 27, 2021 4:01 PM

- Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis in 4Q 2021 - - On track to initiate DMT310 Phase 2 study for moderate to severe rosacea in 4Q 2021 - SAN DIEGO, CA / ACCESSWIRE / September 27, 2021 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company...

Read more

Mosaic ImmunoEngineering Announces Keynote Presentation Highlighting its Modular Vaccine Platform Delivery Technology

September 27, 2021 8:55 AM

- Presentation highlighted potential of polymer-based delivery system for slow-release of vaccines that potentially require no booster shots - - Delivery system is transportation and storage friendly with no refrigeration or freezing requirements - NOVATO, CA / ACCESSWIRE / September 27, 2021 / Mosaic ImmunoEngineering Inc. ("Mosaic" or the "Company"), (OTCQB:CPMV), a development-stage biotechnology company focused on bridging immunology and...

Read more

Hancock Jaffe to Participate in the Duologue Series Virtual Webinar Hosted by Ladenburg Thalmann

September 24, 2021 9:00 AM

Live webinar followed by Q&A on Monday, September 27th at 1:00 PM ET with Robert Berman Chief Executive Officer of Hancock Jaffe Laboratories IRVINE, CA / ACCESSWIRE / September 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI) ("Hancock Jaffe" or the "Company"), a medical device company focused on improving the standard of care in the treatment of venous disease, today announced that Robert Berman, CEO of Hancock Jaffe will participate...

Read more

Applied UV Declares Monthly Preferred Stock Dividend

September 24, 2021 8:30 AM

MOUNT VERNON, NY / ACCESSWIRE / September 24, 2021 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), an infection control technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of...

Read more

Mosaic ImmunoEngineering Announces Publication of Data Supporting the Potential of Its SARS-CoV-2 Vaccine Candidates under its Modular Vaccine Platform

September 23, 2021 9:00 AM

Vaccine candidates triggered high production of neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1 in preclinical studies Epitopes used in the vaccine candidates are located in regions that are not known to be susceptible to mutations, including the SARS-CoV-2 Delta Variant The vaccine candidates are stable at room temperature and can be administered using the Company's MVP technology eliminating the need for multiple doses NOVATO, CA /...

Read more

The Future Of Personalized Medicine For Mental Illness by Dr. Riyad Domingo

September 23, 2021 8:30 AM

CAPE TOWN, SA / ACCESSWIRE / September 23, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("WGG'' or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research is pleased to share the following update: Newly appointed Chief Innovation Officer of M2Bio Sciences, Dr. Riyad Domingo, will present his inaugural webinar on the future of mental health therapeutics derived from the psychedelic...

Read more

CB Scientific, Inc. (CBSC) enters into a Consultant Services Agreement with the Dorchester Group LLC

September 23, 2021 6:00 AM

ESCONDIDO, CA/ ACCESSWIRE/ September 23, 2021 / CB Scientific. Inc. (OTC PINK:CBSC) ("CBSC" or the "Company"), a provider of remote cardiac monitoring products and services (my-Cam™ monitor and my-Cardia™ cloud-based software portal), both domestically and internationally, today announced that it has hired and enter into a consultant services agreement with the Dorchester Group LLC, and its President Robert H. Hesse, to assist and advise the...

Read more

Notice of Extra General Meeting in Biovica International AB

September 23, 2021 2:20 AM

UPPSALA, SE / ACCESSWIRE / September 23, 2021 / Biovica International (STO:BIOVIC-B) (STO:BIOVIC.B) (FRA:9II) The shareholders of Biovica International AB, reg. no. 556774-6150, (the "Company") are hereby invited to the extra general meeting on Tuesday 12 October 2021. Information with respect to the coronavirus  The Company is mindful of the health and well-being of its shareholders and employees. It´s important for the Company to take a social...

Read more

Viewpoint Molecular Targeting(R) Announces Publication of Preclinical Data of VMT01 in Peer-Reviewed Journal, "Cancers"

September 22, 2021 10:00 AM

Viewpoint advancing new, proprietary class of personalized 212 Pb-based alpha-particle radiopharmaceuticals to transform the treatment landscape of radiotherapies for cancer Positive preclinical data have demonstrated that a single dose of [212 Pb]VMT01 has significantly arrested melanoma tumor growth and extended survival The combination of [212 Pb]VMT01 and immune checkpoint inhibitors produced a 43% complete and durable response rate in this...

Read more

Hancock Jaffe Announces Corporate Rebranding to Reflect Prioritization of its Development Pipeline on Venous Disease Programs

September 21, 2021 4:00 PM

- Hancock Jaffe changing name to enVVeno Medical Corporation and ticker symbol to NASDAQ: NVNO, effective October 1, 2021 - - Development strategy to focus on venous disease and advancement of the VenoValve® - - Initiated development of second product for the treatment of venous disease; expected to be unveiled in mid-2022 - - Management to host a conference call with live video webcast at 4:30 p.m. ET today, September 21st - IRVINE, CA /...

Read more

Black Bird Biotech Seeks Approval in All Remaining States, to Open Up Entire US Market, Including the Projected $45 Billion Cannabis Industry, for its Disruptive Plant-Based MiteXstreamTM Biopesticide Sales Efforts

September 21, 2021 8:30 AM

FLOWER MOUND, TX / ACCESSWIRE / September 21, 2021 / Black Bird Biotech, Inc. (OTC PINK:BBBT), manufacturer of plant-based MiteXstreamTM biopesticide, today announced that, on the heels of its first sales of its game-changing biopesticide, MiteXstreamTM, it is seeking approval of MiteXstreamTM in the remaining 35 states and in D.C. to more readily provide much-needed crop protection, both indoor and outdoor, to the dynamic cannabis industry, one...

Read more

Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Dermatologic Surgery (ASDS) 2021 Annual Meeting

September 21, 2021 8:00 AM

The presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin for multiple aesthetic skin conditions SAN DIEGO, CA / ACCESSWIRE / September 21, 2021 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical...

Read more

Mosaic ImmunoEngineering Expands Its Modular Vaccine Platform (MVP) Through New Technology Licensing Agreement with the University of California San Diego

September 21, 2021 8:00 AM

- Licensed Candidates Hold Potential to Address Emerging SARS-CoV-2 and other Infectious Diseases Including Human and Veterinary Applications - - Data Supporting the Potential of Lead Vaccine Candidates was Funded Through Competitive Federal Grants and has Been Published in Peer Reviewed Scientific Publications - - MVP Combines Protein Nanoparticle-Based Adjuvants Linked to Infectious Disease Peptides for Rapid Development of Thermally Stable...

Read more

Helix BioPharma Corp. Announces Appointment of Interim Chief Executive Officer

September 20, 2021 5:23 PM

RICHMOND HILL, ON / ACCESSWIRE / September 20, 2021 / Helix BioPharma Corp. (TSX:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Company's Chairman of the Board, Prof. Dr. Slawomir Majewski, will immediately assume the role of Interim CEO while the Company continues to identify and evaluate candidates. About Helix BioPharma...

Read more

Bakhu Holdings, Corp. Announces Appointment of Teddy C. Scott As CEO and Chair of the Board

September 20, 2021 8:43 AM

LONG BEACH, CA / ACCESSWIRE / September 20, 2021 / Bakhu Holdings, Corp. (OTC PINK:BKUH) today announced that Teddy C. Scott, 55, Ph.D., J.D., has accepted positions as CEO and Chair of the Board for the cell replication technology company. Scott, known as "Teddy" throughout the industry, has more than 20 years in biotechnology research, intellectual property law and the cannabis industry. Teddy has been recognized for his leadership in the...

Read more

Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients

September 20, 2021 8:00 AM

Study unblinded due to strong efficacy signal for 28-day mortality endpoint Critically ill patients demonstrated a 68.5% reduction in the risk of dying when treated with EB05 over Standard of Care Data monitoring board recommends continuation to confirmatory Phase 3 study TORONTO, ON / ACCESSWIRE / September 20, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related...

Read more

Medspresso Announces Additional Speciality Coffees To The Range

September 17, 2021 8:30 AM

CAPE TOWN, SA / ACCESSWIRE / September 17, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) ("Wuhan" or the "Company"), a bioceutical company focused on alternative plant-based cannabinoids and psilocybin medical research, is pleased to announce the following corporate update: M2Bio Sciences Food and Beverage is thrilled to launch the Medspresso CBD Infused Organic Whole Bean and Ground Coffee Range. The range will consist of two Speciality...

Read more

ITOCO Receives Final Agreement on an Initial 1,014 Hectares of Nopal Cactus Plantations in Mexico for the Purpose of Carbon Credit Capture; and Will Attend "Dia Internacional Del Nopal En Mexico"

September 16, 2021 7:30 AM

TORONTO, ON / ACCESSWIRE / September 16, 2021 / ITOCO INC. (OTC PINK:ITMC) is pleased to have received final signatures on an initial 1,014 hectares of Nopal Cactus Plantations in State of Mexico and Hidalgo State, Mexico from 125 individual farmers. ITOCO has applied to "Verra Standard (VCS)" for the certification of approximately US $750k in Carbon Credits based on the extractive properties of the Nopal Cactus plant vis a vis Carbon on this...

Read more

Vaccine Developer Intravacc Launches Hybrid Business Model to Drive Innovation and Growth

September 16, 2021 7:00 AM

Hybrid model: CDMO services and development of own vaccine pipeline Intravacc will also put emphasis on the therapeutic vaccine market Intravacc's own vaccine portfolio will mainly focus on intranasal administration Intravacc launches promotional campaign for funding of phase I clinical trials of Avacc 10 nasal spray vaccine BILTHOVEN, THE NETHERLANDS / ACCESSWIRE / September 16, 2021 / Intravacc, a global leader in translational research and...

Read more

RepliCel and University of Victoria Collaboration Leads to Bioengineering Innovations, Funding, and Patents

September 16, 2021 6:00 AM

Canadian granting agency MITACS commits to three years of funding for the project's second stage to optimize certain proprietary microcarrier technologies for use in RepliCel's cell therapy manufacturing RepliCel signs an Option to License agreement related to a filed US patent application VANCOUVER, BC / ACCESSWIRE / September 16, 2021 / RepliCel Life Sciences Inc. (OTCQB:REPCF)(TSXV:RP)(FRA:P6P2) ("RepliCel" or the "Company"), a company...

Read more